Transfusion-driven hyperhemolysis in sickle cell disease
镰状细胞病中输血引起的高溶血症
基本信息
- 批准号:10690278
- 负责人:
- 金额:$ 80.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-13 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdultAnemiaAntibodiesAutologousBindingBiological AssayBiological MarkersBlocking AntibodiesBlood CirculationBone MarrowBone Marrow SuppressionCFU-ECell Culture SystemCell LineCellsCessation of lifeComplicationDataDefectDevelopmentDiagnosisEPOR geneEatingErythroblastsErythrocyte TransfusionErythrocytesErythroidErythroid CellsErythrophagocytosisErythropoiesisFc ReceptorGrowthHemeHemoglobinHemoglobinopathiesHemolysisHemolytic AnemiaHumanImmuneImpairmentIn VitroInflammatoryInterferon Type IInterferonsIron ChelationKnock-outKnockout MiceLifeLigandsMediatingModelingMolecularMusPathologicPathway interactionsPatientsPhagocytesPhagocytosisPhosphorylationPlasmaPreventionProductionProteinsReactionRecoveryReticulocytesRoleSTAT1 geneSTAT2 geneSYK geneSamplingSavingsSeveritiesSickle CellSickle Cell AnemiaSignal TransductionSignaling MoleculeTestingTherapeuticTherapeutic EffectThrombospondin 1ThrombospondinsTimeTransfusionUp-Regulationbasecell agecell typecrosslinkeffective therapyexperiencein vivomacrophagemonocytemouse modelnew therapeutic targetpatient populationprematurepreventreceptorrisk stratificationsicklingtargeted treatmenttherapeutic evaluationuptake
项目摘要
Red blood cell (RBC) transfusions remain a cornerstone treatment in the management of sickle cell disease
(SCD). However, patients may experience delayed hemolytic transfusion reaction (DHTR) which in this patient
population has an unpredictable progression from mild to life-threatening severe reactions where both transfused
and patient’s own RBCs are destroyed along with reticulocytopenia at the time of hemolytic crisis, exacerbating
the anemia. The mechanisms underlying severe DHTR progression are poorly understood, posing challenges
for prevention and effective treatments for this transfusion complication which is disproportionately encountered
in patients with SCD. We recently found that acute hemolysis induces type I interferon (IFN-I) production in innate
immune cells, leading to increased differentiation and activation of monocyte-derived macrophages (MoMΦ) in
SCD, and exacerbating destruction of antibody (Ab)-coated transfused RBCs. Our preliminary data showed that
Ab-sensitized RBC destruction alone also led to IFN-I production but with even higher levels if destruction
occurred under hemolytic conditions, which interestingly also induced bystander hemolysis of sickle RBCs,
mimicking hyperhemolysis reaction in SCD. We also found that hemolysis-induced IFN-I impairs erythropoiesis
along with inhibition of EPO/EPOR signaling. Based on these data, we hypothesize that Fc receptor crosslinking
in a hemolytic backdrop of SCD leads to increase in IFN-I levels, causing heightened IFN-I signaling in
phagocytes and erythroid cells which trigger increased RBC destruction and further suppression of RBC
production, respectively, leading to severe DHTR. In aim 1, we will focus on identifying mechanisms of bystander
hemolysis by examining the role of key phagocytosis activation molecules, specifically SCD associated eat me
signals including thrombospondin (TSP-1) and its ligands which are upregulated in hyperhemolytic models. We
will compare the role of Ab-mediated erythrophagocytosis versus Ab-independent RBC engulfment in triggering
bystander hemolysis and interrogate the relative contribution of inhibiting FcR/SYK phosphorylation and heme
activation pathways in autologous sickle RBC destruction. We will also examine the potential of IFN-I as a
biomarker of DHTR severity by examining IFN-I/STAT1 driven changes in monocytes in SCD patient samples,
comparing patients experiencing severe and mild DHTR and after recovery to steady state. For aim 2, we will
define the mechanisms by which IFN-I suppresses erythropoiesis using primary erythroid cell culture system and
targeted deletion of key downstream pathways in human erythroblast cell lines and mouse models. We will also
test the therapeutic effects of inhibiting IFN-I production/IFN-I signaling or/and increasing EPO/EPOR signaling
on reversing impaired BM erythropoiesis in SCD mice and on human erythropoiesis in vitro and in cultures
treated with SCD patient plasma. We believe that our proposed studies to examine the basis for progression to
DHTR severity may help stratify risk and aid in development of novel targeted therapies to reverse or prevent
hyperhemolysis, a devastating complication of an otherwise life-saving treatment in SCD.
红细胞(RBC)输注仍然是治疗镰状细胞病的基石
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xiuli An其他文献
Xiuli An的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xiuli An', 18)}}的其他基金
Transfusion-driven hyperhemolysis in sickle cell disease
镰状细胞病中输血引起的高溶血症
- 批准号:
10668756 - 财政年份:2023
- 资助金额:
$ 80.4万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 80.4万 - 项目类别:
Research Grant